Last updated: June 30, 2026

Prometh Plain (promethazine) market dynamics and financial trajectory: pricing pressure, utilization trends, and competitive/IP risks

Prometh Plain is a brand-name promethazine product with limited public segment-level profitability disclosures. The commercial trajectory for promethazine oral products is typically dominated by: (1) long-established generic competition, (2) periodic price resets driven by wholesaler rebates and state Medicaid/340B contracting, and (3) lower incremental demand growth versus newer antiemetic and allergy agents. For business planning, the key financial reality is that “market dynamics” are mostly generic-price and payer-formulary mechanics rather than patent-driven monopoly economics.

What is Prometh Plain and where does it fit in the antinausea antihistamine market?

Prometh Plain is marketed as an oral promethazine formulation, typically positioned in the antihistamine/antiemetic category. Promethazine is used for:

Nausea and vomiting (including motion-related and other etiologies per labeling)
Allergic symptoms (historically, depending on formulation and labeling)
Adjunctive sedation indications (depending on route and label scope)

Market classification and buying behavior

Retail and mail: demand is driven by acute episodes and historical prescriber familiarity.
Institutional: hospital and long-term care utilization depends on formulary placement and therapeutic interchangeability.
Payer dynamics: promethazine is frequently a “low-cost preferred” option where generics are available.

Core commercial implication Because promethazine’s active ingredient is off-patent in most major markets, the economic model for Prometh Plain is usually anchored in contracting, channel mix, and differential positioning (packaging, strengths, and distribution footprint) rather than exclusivity.

How do generic promethazine dynamics affect Prometh Plain pricing power?

The promethazine category is characterized by:

Wide generic availability (multiple manufacturers)
High price competition once new entrants launch
Low tolerance for premium pricing by payers once a generic is present

Mechanisms that compress brand margins

Wholesaler and pharmacy benefit manager (PBM) contracting: rebates and fees shift economic value from branded to generic SKUs.
Formulary switching: health plans often prefer A-rated generics or single-source “best value” listings.
State Medicaid reimbursement: typically enforces low net pricing for older generics through fee schedule and preferred drug policies.
Pharmacy dispensing economics: low ingredient cost products reduce brand differentiation.

Financial trajectory pattern (typical)

Early years after brand launch: modest premium pricing and share capture.
Mid-life: steady conversion to generics in eligible channels.
Late life: promotional spend declines, net revenue becomes highly sensitive to net-to-gross and contracting.

What is the Orange Book status of Prometh Plain and what does it imply for exclusivity?

Orange Book exclusivity and patent coverage determine brand durability only when patents or regulatory exclusivities still block generic entry. For promethazine oral products in the US, generic entry has historically occurred for the active ingredient and many formulation variants.

Business implication

If Prometh Plain is not listed with unexpired patents/exclusivities relevant to the marketed NDA route/strength/form, it generally faces ongoing generic interchangeability.
In that scenario, financial trajectory is driven by “net price survival” rather than exclusivity cliffs.

Actionable diligence for commercial stakeholders

Map Prometh Plain’s exact marketed strength, dosage form, and NDA/label code to Orange Book entries (active ingredient scope and formulation/method-of-use coverage).
Track whether any unexpired patents still align to the specific claim sets protecting the marketed formulation.

When does Prometh Plain lose exclusivity, and how should that be reflected in revenue forecasts?

For older small-molecule brands, “exclusivity loss” usually occurs through one of these routes:

Active ingredient patent expiration
Formulation or method-of-use patent expiration
Loss of regulatory exclusivity from an NDA submission (rare for older actives if already superseded)

Forecasting consequence

Revenue typically steps down at generic launch rather than gradients over years.
After the initial entry, revenues stabilize at a lower base if the brand retains some channel-specific presence, but net pricing keeps trending toward generic parity.

Modeling approach

Assume step-down elasticity to generic availability.
Use channel-specific share assumptions (retail vs institutional).
Build sensitivity around payer rate changes and rebate renegotiations.

How many patents cover promethazine oral formulations like Prometh Plain, and what claim types matter most?

Where patent coverage exists, it typically clusters into:

Composition of matter (often long expired for promethazine as an active ingredient)
Formulation (excipients, salts, or dosage-form engineering)
Method of use (specific dosing regimens, indications)
Manufacturing process (rarely a dominant driver for older oral generics)

Business implication For a product like Prometh Plain, any remaining defensible value would most likely come from:

A still-protected formulation variant or packaging-related claim (less common)
A still-relevant method-of-use claim matched to labeling (if it exists, it can create a narrow protection wedge)

Without intact, label-matched patent coverage, generics typically treat the product as substitutable.

What patent litigation affects Prometh Plain and other generic-entry risks for promethazine brands?

For legacy small-molecule products, Paragraph IV challenges (Hatch-Waxman) are usually:

Active ingredient or formulation triggers
Settled via license or “at-risk” launch schedules

Typical commercial impact

If a brand litigates and loses, the generic launch accelerates and brand revenue compresses.
If a brand settles early, the settlement can delay entry but requires careful reading of:
- Launch date caps
- Authorized generic timing
- Territory and exclusivity carve-outs
- “No further patent” covenants

Business implication for Prometh Plain

The financial trajectory depends on whether any settlement caps remain in force and whether they map to the exact NDA/strength.

Which generic companies compete most directly with promethazine oral products, and how does that drive pricing?

Promethazine oral products usually have multiple ANDA entrants across strengths and dosage forms. Competitive pricing pressure typically intensifies when:

Multiple generics are in stock and pharmacists can switch easily
A PBM runs a consolidated preferred list for the lowest net cost
Institutional formularies support therapeutic interchange

Commercial consequence

Prometh Plain’s net revenue per unit usually declines faster than unit volume.
Marketing spend becomes less effective at offsetting price compression.

How does Prometh Plain compare financially with other promethazine and antiemetic oral options?

Promethazine competes with:

Other first-generation antihistamines with antiemetic labeling (depending on formulary and patient history)
Newer antiemetics (some are more pathway-specific and may command higher price points)
Non-pharmacologic and alternative regimen choices (especially where modern protocols exist)

Financial comparison framing

Promethazine’s “value tier” is usually low cost.
That tiering means branded retention depends on contracting structure and channel behavior, not therapeutic differentiation.

What is the FDA regulatory pathway status of Prometh Plain and how does that shape generic substitution?

Once a product is sufficiently old and generics exist, substitution is shaped by:

Bioequivalence and substitutability under FDA’s “same active ingredient, same dosage form/strength” concepts
Labeling parity and therapeutic equivalence acceptance by payers
Pharmacy formulary rules that prompt automatic switching

Commercial implication

Even if Prometh Plain retains a brand presence, substitution makes it vulnerable to “lost demand” at the point of dispensing.

What manufacturing and supply-chain risks exist for Prometh Plain’s long-tail revenue?

For oral generics and long-seller brands, supply risks typically arise from:

API sourcing constraints
Manufacturing line downtime
Container closure system changes or stability commitments
Regulatory inspections affecting batch release timing

Financial trajectory effect

Short supply can briefly lift net pricing, but for widely substitutable products the rebound is usually limited.
Persistent quality events can cause longer channel reallocation to other SKUs.

How do wholesalers, PBMs, and Medicaid contracting dynamics determine Prometh Plain net revenue?

Net revenue for older oral brands is structurally driven by:

Rebates and fees (PBMs and group purchasing organizations)
Medicaid state reimbursement policies
340B eligibility (if applicable for dispensing settings, which often changes economics)
Commercial payer formularies and step therapy requirements (less common for low-cost generics but can occur)

Business implication

Prometh Plain profitability is typically “contracting-sensitive,” not “innovation-sensitive.”

What generic entry scenarios could most threaten Prometh Plain volume and pricing?

The main entry scenarios are:

Additional ANDA approvals for the same strength/dosage form
Authorized generic launches that pull retail demand immediately
Switch-based formulary updates that collapse multiple SKU options into one preferred product

Threat ranking (typical)

Authorized generic or rapid multiple generic launches in a short window
PBM preferred-list tightening
Institutional formulary “therapeutic interchange” moves

How strong is the patent estate for Prometh Plain compared with similar legacy antihistamine brands?

For most legacy promethazine brands, patent estates are usually weak on:

Composition-of-matter (expired)
Generic blocking patents (not label-matched or expired)
Method-of-use claims (narrow and easily designed around)

Commercial implication

The competitive floor is usually set by generic net price rather than patent strength.

What does Prometh Plain’s financial trajectory likely look like across the brand lifecycle?

Given promethazine’s mature market status, the likely lifecycle resembles:

Plateau after initial adoption
Gradual share loss as generics expand
Periodic net revenue resets tied to contracting cycles
Low growth or decline as substitutes remain abundant

Revenue driver decomposition

Volume: declines with generic share capture and substitutability
Net price: declines with rebate renegotiations and competitive tendering
Promotional intensity: typically reduces over time, limiting incremental share gain

Key Takeaways

Prometh Plain’s financial trajectory is primarily governed by generic-price competition and contracting mechanics rather than patent exclusivity.
Net revenue is structurally sensitive to PBM rebates, Medicaid reimbursement, and preferred formulary placement.
The biggest downside risks come from additional generic/authorized generic entries and formulary consolidation that accelerates dispensing switching.
Patent estate strength, where still relevant, must be mapped to the exact NDA/strength/dosage form and claim types that can block label-matched generics.

FAQs

1) Will promethazine oral brands lose more value from authorized generic launches than from additional ANDAs?

Authorized generics often accelerate retail and mail switching because they combine rapid availability with tight pricing, compressing brand net price quickly.

2) Do Medicaid reimbursement policies usually accelerate generic switching for low-cost antihistamine antiemetics?

Yes. Medicaid rate setting and preferred policies typically reinforce generic substitution, reducing branded persistence.

3) Can formulation patents extend brand value for promethazine oral products?

Only if a still-valid formulation patent is tightly matched to the marketed dosage form and strength such that a generic cannot design around without loss of approval parity.

4) How do PBMs typically influence promethazine brand economics?

PBMs steer dispensing toward preferred SKUs through rebate-driven net pricing and formulary tier placement, shifting economic value from brand to generic.

5) What supply events most affect small oral brands like promethazine products?

API or manufacturing batch-release issues that reduce supply can temporarily change net pricing, but broad substitutability usually limits lasting revenue gains.

References (APA)

(No sources were provided in the prompt, and no cited bibliographic material can be produced without external verification.)

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	110
Clinical Trials:	1
Patent Applications:	2,747
DailyMed Link:	PROMETH PLAIN at DailyMed

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Actavis Mid Atlantic	PROMETH PLAIN	promethazine hydrochloride	SYRUP;ORAL	085953-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

PROMETH PLAIN Drug Patent Profile

Which patents cover Prometh Plain, and what generic alternatives are available?

DrugPatentWatch^® Litigation and Generic Entry Outlook for Prometh Plain

AI Deep Research

Questions you can ask:

Summary for PROMETH PLAIN

Recent Clinical Trials for PROMETH PLAIN

US Patents and Regulatory Information for PROMETH PLAIN